Humanigen, Inc. provided the following regulatory updates on lenzilumab™: Lenzilumab in COVID-19: On June 30, 2022, the Company issued a press release confirming that the Company had received notice from the National Institute of Allergy and Infectious Diseases (“NIAID”) that it has completed database lock for its Big Effect Trial of lenzilumab (“BET-B”) being conducted in collaboration with the National Institutes of Health (“NIH”) public-private partnership Accelerating COVID-19 Therapeutic Innovations and Vaccines-5 (“ACTIV-5”). The Company expects to receive topline results from NIH/NIAID in July. Lenzilumab in chimeric antigen receptor T-cell (“CAR-T”) The Company's study to evaluate the efficacy and safety of lenzilumab combined with two FDA-approved CAR-T therapies in non-Hodgkin lymphomas, known as SHIELD, is now expected to dose its first patient in the third quarter of 2022.

SHIELD will study lenzilumab for the prevention of CAR-T therapy-related toxicities including immune effector cell associated neurotoxicity (“ICANS”) and cytokine release syndrome (“CRS”). Lenzilumab in Acute Graft versus Host Disease (“aGvHD”): The study of lenzilumab as a companion to allogeneic hematopoietic stem cell therapy (“HSCT”) for patients with hematological cancers to prevent/treat aGvHD conducted by the IMPACT Partnership in the United Kingdom, known as the RATinG study, is now expected to dose its first patient in the third quarter of 2022.